drugset / Trial / NCT06808984
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Timeline
- Start
- 2025-06-09
- Primary completion
- 2027-11-26
- Completion
- 2028-01-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986368 | Unknown | — | Oral |